Susquehanna International Group’s Dr. Reddy's Laboratories RDY Stock Holding History

Susquehanna International Group’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,900	Closed	-$172K	–	13291
2024 Q4	$172K	Buy	+10,900	New	+$164K	﹤0.01%	10891
2022 Q3	–	Sell	-20,000	Closed	-$222K	–	13960
2022 Q2	$222K	Sell	20,000 -3,000	-13%	-$32.6K	﹤0.01%	10375
2022 Q1	$256K	Buy	+23,000	New	+$261K	﹤0.01%	10661
2021 Q4	–	Sell	-111,500	Closed	-$1.45M	–	13765
2021 Q3	$1.45M	Buy	111,500 +58,000	+108%	+$773K	﹤0.01%	6568
2021 Q2	$787K	Buy	53,500 +31,500	+143%	+$441K	﹤0.01%	8421
2021 Q1	$270K	Sell	22,000 -39,500	-64%	-$507K	﹤0.01%	10822
2020 Q4	$877K	Buy	61,500 +8,000	+15%	+$108K	﹤0.01%	7025
2020 Q3	$744K	Sell	53,500 -18,500	-26%	-$220K	﹤0.01%	6830
2020 Q2	$763K	Buy	72,000 +27,500	+62%	+$280K	﹤0.01%	6488
2020 Q1	$359K	Buy	44,500 +5,000	+13%	+$41.7K	﹤0.01%	7634
2019 Q4	$321K	Buy	+39,500	New	+$312K	﹤0.01%	7889
2019 Q3	–	Sell	-29,500	Closed	-$221K	–	10709
2019 Q2	$221K	Buy	+29,500	New	+$232K	﹤0.01%	8934
2018 Q4	–	Sell	-37,000	Closed	-$256K	–	9794
2018 Q3	$256K	Buy	+37,000	New	+$247K	﹤0.01%	7781
2018 Q2	–	Sell	-32,000	Closed	-$209K	–	10255
2018 Q1	$209K	Sell	32,000 -2,500	-7%	-$17.5K	﹤0.01%	8256
2017 Q4	$259K	Sell	34,500 -494,500	-93%	-$3.56M	﹤0.01%	7828
2017 Q3	$3.77M	Buy	529,000 +495,500	+1,479%	+$3.56M	﹤0.01%	2891
2017 Q2	$282K	Buy	33,500 +2,500	+8%	+$20.3K	﹤0.01%	7695
2017 Q1	$249K	Buy	+31,000	New	+$268K	﹤0.01%	7677
2016 Q4	–	Sell	-22,000	Closed	-$204K	–	10048
2016 Q3	$204K	Buy	+22,000	New	+$210K	﹤0.01%	7556
2016 Q1	–	Sell	-78,000	Closed	-$722K	–	9540
2015 Q4	$722K	Buy	78,000 +55,500	+247%	+$608K	﹤0.01%	6074
2015 Q3	$288K	Buy	+22,500	New	+$279K	﹤0.01%	8104
2014 Q3	–	Sell	-27,500	Closed	-$237K	–	9849
2014 Q2	$237K	Sell	27,500 -26,000	-49%	-$219K	﹤0.01%	8782
2014 Q1	$470K	Buy	53,500 +15,000	+39%	+$130K	﹤0.01%	6828
2013 Q4	$316K	Buy	+38,500	New	+$305K	﹤0.01%	7501

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $345M AUM 10.59% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Susquehanna International Group's RDY Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Dr. Reddy's Laboratories (RDY) in Q1 2026: 42,300 shares worth $586K. The stake represents ﹤0.01% of the portfolio and ranks #9250 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in RDY as recently as Q1 2024.

Susquehanna International Group first reported a position in RDY in Q2 2013 and has held it in 20 quarters since. The position peaked at $2.79M in Q4 2015. 248 funds tracked by Wall St. Rank hold RDY as of Q1 2026.

Susquehanna International Group held 42,300 shares of Dr. Reddy's Laboratories worth $586K as of Q1 2026.
Dr. Reddy's Laboratories was a new Susquehanna International Group position in Q1 2026.
Dr. Reddy's Laboratories made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9250 holding.
Susquehanna International Group first reported a position in Dr. Reddy's Laboratories in Q2 2013 and has held it in 20 quarters since.
Susquehanna International Group's Dr. Reddy's Laboratories position peaked at $2.79M in Q4 2015.
248 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.